Celator shares surge as Phase III results for Vyxeos show improved survival rates in acute myeloid leukemia

16 March 2016

Shares in biopharma company Celator Pharmaceuticals (Nasdaq: CPXX) soared by more than 400% on Tuesday after announcing improved survival rates in a Phase III trial for Vyxeos, a drug treating acute myeloid leukemia (AML).

The company, based in the USA and Canada, is now planning to submit a New Drug Application for Vyxeos with the US Food and Drug Administration later this year, and to submit a Marketing Authorization Application with the European Medicines Agency in early 2017.

A medium survival period of 9.56 months was recorded for patients in the trial treated with Vyxeos, compared to 5.95 months for patients who received the standard treatment of cytarabine and daunorubicin known as 7+3.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK